Glioblastoma is the most common primary brain tumour in humans. It is a diagnosis with a very bleak outcome. The goal is to analyse whether glioblastoma expresses C1-IA and CRP (proteins) that inhibit immune response by inactivating the complement system, and to test treatment in various animal models for glioblastoma. Different administering forms will be tested to study how the immune system is affected. The long-term goal is to find an alternative for all those patients who receive the dismal diagnosis, glioblastoma.
Menu